From the Journals

Low-carb breakfast key to lower glucose variability in T2D?


 

FROM THE AMERICAN JOURNAL OF CLINICAL NUTRITION

Intervention improved CGM measures

There was no significant difference in the primary outcome, change in A1c, at the end of 12 weeks, in the two groups. The mean A1c decreased by 0.3% in the intervention group vs 0.1% in the control group (P = .06).

Similarly, in secondary outcomes, weight and BMI each decreased about 1% and waist circumference decreased by about 2.5 cm in each group at 12 weeks (no significant difference). There were also no significant differences in hunger, satiety, or physical activity between the two groups.

However, the 24-hour CGM data showed that mean and maximum glucose, glycemic variability, and time above range were all significantly lower in participants in the low-carbohydrate breakfast intervention group vs. those in the control group (all P < .05).

Time in range was significantly higher among participants in the intervention group (P < .05).

In addition, the 2-hour postprandial CGM data showed that mean glucose and maximum glucose after breakfast were lower in participants in the low-carbohydrate breakfast group than in the control group.

This work was supported by investigator-initiated operating grants to senior author Jonathan P. Little, PhD, School of Health and Exercise Sciences, University of British Columbia, from the Egg Nutrition Center, United States, and Egg Farmers of Canada. The authors declare that they have no relevant financial relationships.

A version of this article originally appeared on Medscape.com.

Pages

Recommended Reading

Beta-blocker gel shows promise for diabetic foot ulcers
Federal Practitioner
Does Ozempic cause hair loss?
Federal Practitioner
Younger age of type 2 diabetes onset linked to dementia risk
Federal Practitioner
Diabetes, cholesterol meds use drops after bariatric surgery
Federal Practitioner
FDA approves new drug, sotagliflozin, for heart failure
Federal Practitioner
Troponin to ID diabetes patients with silent heart disease?
Federal Practitioner
Positive top-line results for cannabinoid-based med for nerve pain
Federal Practitioner
FDA warns people to avoid compounded semaglutide medicines
Federal Practitioner
Continuous glucose monitors come to hospitals
Federal Practitioner
Medicaid patients with heart failure get poor follow-up after hospital discharge
Federal Practitioner